3rd Quarter - Report
PHARMATHENE, INC for PHARMATHENE, INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Firm
Client
Income
—
Expenses
$207,464
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 23, 2008 | $207,464 | Replaced |
| 3rd Quarter - Termination | Aug 25, 2009 | $207,464 | Replaced |
| 3rd Quarter - Amendment | Oct 20, 2009 | $207,464 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Health & Human Services (HHS) anthrax vaccine and antitoxin. Avanced research and development. BARDA funding. Project Bioshield. Biodefense
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK EDWARD COOKE | Lobbyist, Government Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.